Pulse Biosciences, Inc. (NASDAQ:PLSE) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07.Submission of Matters to a Vote of Security Holders.
On May 23, 2018, Pulse Biosciences, Inc. (the “Company”) held its Annual Meeting at the Fairfield Inn & Suites located at 25921 Industrial Boulevard, Hayward, California 94545. The stockholders of the Company voted on the following items at the Annual Meeting:
|
1. |
To elect six directors to hold office until the Company’s 2019 annual meeting and until their successors are duly elected and qualified, subject to earlier resignation or removal; |
|
2. |
To approve the reincorporation of the Company from the State of Nevada to the State of Delaware; |
|
3. |
To approve the adoption of the Company’s Form of Indemnification Agreement; and |
|
4. |
To ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018. |
The voting results for each of these proposals are detailed below:
|
Nominee |
For |
Against |
Abstained |
Broker Non-votes |
|
Darrin R. Uecker |
9,027,345 |
96,741 |
303,929 |
5,690,354 |
|
Robert W. Duggan |
9,023,765 |
104,094 |
300,156 |
5,690,354 |
|
Thomas J. Fogarty, M.D. |
9,051,430 |
68,552 |
308,033 |
5,690,354 |
|
Manmeet S. Soni |
9,069,344 |
50,633 |
308,038 |
5,690,354 |
|
Kenneth A. Clark |
8,815,022 |
304,955 |
308,038 |
5,690,354 |
|
Maky Zanganeh, D.D.S |
9,069,343 |
51,957 |
306,715 |
5,690,354 |
Each director nominee was duly elected to serve until the 2019 annual meeting of stockholders and until his or her successor is duly elected and qualified.
|
2. Reincorporation of the Company from the State of Nevada to the State of Delaware |
|
For |
Against |
Abstained |
Broker Non-votes |
|
8,741,618 |
377,913 |
308,484 |
5,690,354 |
The stockholders approved the reincorporation of the Company from the State of Nevada to the State of Delaware, as described in the proxy materials.
|
3. Adoption of the Form of Indemnification Agreement |
|
For |
Against |
Abstained |
Broker Non-votes |
|
8,758,870 |
355,041 |
314,104 |
5,690,354 |
The stockholders approved the adoption of the Company’s Form of Indemnification Agreement, as described in the proxy materials.
|
4. Ratification of Appointment of Independent Registered Public Accounting Firm |
|
For |
Against |
Abstained |
Broker Non-votes |
|
14,727,142 |
43,612 |
347,615 |
N/A |
The stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018.
About Pulse Biosciences, Inc. (NASDAQ:PLSE)
Pulse Biosciences, Inc., formerly Electroblate, Inc., is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue. NPES provides treatment in a range of dermatology and aesthetic applications. It offers treatment for minimally invasive applications, such as cardiac ablation, lung disease, Barret’s esophagus, thyroid nodules, and ear, nose and throat (ENT) papillomas. The Company is developing a system for the delivery of NPES treatments, identified as the PulseTx system (PulseTx). The PulseTx system delivers NPES pulses through its tunable pulse generator and its planned suite of electrodes. The PulseTx system pulses are applied directly to tissue through electrodes, creating transient nanometer pores in cell and organelle membranes.
